AG
CAPR icon

Advisor Group’s Capricor Therapeutics CAPR Stock Holding History

Advisor Group’s Portfolio CAPR Stock Details CAPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-300
Closed -$1K – 5217
2018
Q4 		$1K Hold
300
– – ﹤0.01% 4934
2018
Q3 		$3K Buy
300
+100
+50% +$1.19K ﹤0.01% 4728
2018
Q2 		$3K Buy
+200
New +$2.72K ﹤0.01% 4528

Other funds holding CAPR

Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CBA
Coastal Bridge Advisors Westport, Connecticut $1.41B AUM 24.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $82.4B AUM 19.69% 1-Year Est. Return
AA
Apriem Advisors Irvine, California $1.05B AUM 22.09% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Advisor Group's CAPR Position: Q1 2019 in Review

Advisor Group sold out of Capricor Therapeutics (CAPR) in Q1 2019, closing a stake of 300 shares — an estimated $1K sold.

Advisor Group first reported a position in CAPR in Q2 2018 and held it in 3 quarters. The position peaked at $3K in Q3 2018. 17 funds tracked by Wall St. Rank hold CAPR as of Q1 2019.

  • Advisor Group reported no remaining Capricor Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Advisor Group sold 300 Capricor Therapeutics shares in Q1 2019, an estimated $1K.
  • Advisor Group first reported a position in Capricor Therapeutics in Q2 2018 and held it in 3 quarters.
  • Advisor Group's Capricor Therapeutics position peaked at $3K in Q3 2018.
  • 17 funds tracked by Wall St. Rank held Capricor Therapeutics as of Q1 2019.

Based on Advisor Group's 13F filing for Q1 2019, filed 9 May 2019.